Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Cirrhosis

Free Subscription 23.02.2026 1 BMC Gastroenterol 2 Hepatology 5 J Hepatol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Gastroenterol

1. ZHONG HY, Ma LD, Li JC, Jiang D, et al
   Associations of relative fat mass with metabolic dysfunction-associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017-2023.
   BMC Gastroenterol. 2026;26:139.
   PubMed         Abstract available
   
   

   
   Hepatology

2. VAN KLEEF LA, Pustjens J, Schattenberg JM, Holleboom AG, et al
   Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction.
   Hepatology. 2026;83:591-602.
   PubMed         Abstract available
   
   
3. SCHWIMMER JB, Thai NQN, Noon SL, Ugalde-Nicalo P, et al
   Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study.
   Hepatology. 2026;83:561-574.
   PubMed         Abstract available
   
   

   
   J Hepatol

4. TELLEZ L, Donate J, Albillos A
   Early portopulmonary hypertension: a signal of increased mortality risk in cirrhosis.
   J Hepatol. 2026 Feb 17:S0168-8278(26)00074-7. doi: 10.1016/j.jhep.2026.
   PubMed        
   
   
5. CAI J, Yip TC, Wong GL, Zhang Y, et al
   Global epidemiology of bacterial infections in patients with cirrhosis: a systematic review and meta-analysis.
   J Hepatol. 2026 Feb 16:S0168-8278(26)00071-1. doi: 10.1016/j.jhep.2026.
   PubMed         Abstract available
   
   
6. STERN C, Loustaud-Ratti V, Yurdaydin C, Brancaccio G, et al
   Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.
   J Hepatol. 2026;84:531-542.
   PubMed         Abstract available
   
   
7. EL-SERAG HB, Lopez C, Luster M, Reddy KR, et al
   HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort.
   J Hepatol. 2026;84:578-586.
   PubMed         Abstract available
   
   
8. VILAR-GOMEZ E, Yates KP, Kleiner DE, Behling C, et al
   Genetic and non-genetic drivers of histological progression and regression in MASLD.
   J Hepatol. 2026;84:502-516.
   PubMed         Abstract available
   
   

   
   PLoS One

9. TANVIR L, Afzal K, Abbas A, Amjad A, et al
   Integrating phytochemical analysis and experimental validation of Ziziphus jujuba seed powder and oil to ameliorate CCl4-induced liver fibrosis in sprague dawley rats.
   PLoS One. 2026;21:e0343428.
   PubMed         Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum